BR0009296A - Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto - Google Patents
Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um compostoInfo
- Publication number
- BR0009296A BR0009296A BR0009296-7A BR0009296A BR0009296A BR 0009296 A BR0009296 A BR 0009296A BR 0009296 A BR0009296 A BR 0009296A BR 0009296 A BR0009296 A BR 0009296A
- Authority
- BR
- Brazil
- Prior art keywords
- neural
- cgs
- cells
- neural activity
- prevent
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 208000035475 disorder Diseases 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title abstract 3
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 210000003061 neural cell Anatomy 0.000 title 2
- 210000004027 cell Anatomy 0.000 title 1
- 230000024245 cell differentiation Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000004069 differentiation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000005036 nerve Anatomy 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- -1 Cyclic glycerophosphates Chemical class 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12917899A IL129178A0 (en) | 1999-03-25 | 1999-03-25 | Induction of nerve generation |
| PCT/IL2000/000185 WO2000057865A2 (en) | 1999-03-25 | 2000-03-24 | Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0009296A true BR0009296A (pt) | 2001-12-18 |
Family
ID=11072645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0009296-7A BR0009296A (pt) | 1999-03-25 | 2000-03-24 | Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6914056B1 (enExample) |
| EP (1) | EP1162959B1 (enExample) |
| JP (1) | JP2002540146A (enExample) |
| KR (1) | KR20010112364A (enExample) |
| CN (1) | CN1348375A (enExample) |
| AT (1) | ATE290385T1 (enExample) |
| AU (1) | AU768911B2 (enExample) |
| BR (1) | BR0009296A (enExample) |
| CA (1) | CA2368597A1 (enExample) |
| DE (1) | DE60018554T2 (enExample) |
| HK (1) | HK1042038A1 (enExample) |
| IL (1) | IL129178A0 (enExample) |
| MX (1) | MXPA01009650A (enExample) |
| NZ (1) | NZ514525A (enExample) |
| RU (1) | RU2247557C2 (enExample) |
| WO (1) | WO2000057865A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69912808T2 (de) | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
| JP4836345B2 (ja) * | 2001-04-13 | 2011-12-14 | きみ子 室伏 | 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤 |
| JP4815063B2 (ja) * | 2001-04-13 | 2011-11-16 | きみ子 室伏 | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤 |
| IL148668A0 (en) * | 2002-03-13 | 2002-09-12 | Yeda Res & Dev | Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy |
| IL148665A0 (en) * | 2002-03-13 | 2002-09-12 | Yeda Res & Dev | Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants |
| AU2003220521A1 (en) * | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Methods of treatment with lxr modulators |
| JP4162927B2 (ja) | 2002-06-11 | 2008-10-08 | きみ子 室伏 | カルバ環状ホスファチジン酸誘導体 |
| US8101552B2 (en) * | 2005-03-14 | 2012-01-24 | Yeda Research And Development Company Ltd. | Cyclic phosphates as plant growth regulators |
| ES2518371T3 (es) * | 2006-04-26 | 2014-11-05 | Toyama Chemical Co., Ltd. | Inductor de la neurogénesis o agente terapéutico para la neuropatía que comprende un derivado de éter alquílico o una sal del mismo |
| KR20090097943A (ko) * | 2006-12-28 | 2009-09-16 | 오짜노미즈 유니버시티 | 환상 포스파티딘산 유도체를 포함하는 진통제 |
| EP2389348B1 (en) * | 2009-01-09 | 2017-11-15 | Sigma-Aldrich Co. LLC | Process for the synthesis of beta glycerol phosphate |
| WO2011065480A1 (ja) * | 2009-11-26 | 2011-06-03 | 国立大学法人お茶の水女子大学 | 神経細胞死抑制剤 |
| WO2014115885A1 (ja) | 2013-01-28 | 2014-07-31 | 国立大学法人お茶の水女子大学 | 脱髄疾患治療薬 |
| EP2807925A1 (en) * | 2013-05-26 | 2014-12-03 | Symrise AG | Antimicrobial compositions |
| EP3386995A1 (en) * | 2015-12-08 | 2018-10-17 | Retrophin, Inc. | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63037A (en) * | 1981-06-04 | 1985-12-31 | Israel State | Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them |
| US5565439A (en) * | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
| JPH06228169A (ja) * | 1993-02-05 | 1994-08-16 | Sagami Chem Res Center | １−ｏ−アシルグリセロール２，３−ホスフェートの製造法 |
| JPH07149772A (ja) * | 1993-11-26 | 1995-06-13 | Sagami Chem Res Center | タンパク質リン酸化酵素ｃの活性促進剤 |
| JPH07258278A (ja) * | 1994-03-18 | 1995-10-09 | Sagami Chem Res Center | １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤 |
| JPH0925235A (ja) * | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤 |
| US6150345A (en) * | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
| IL129179A0 (en) | 1999-03-25 | 2000-02-17 | Yeda Res & Dev | Cyclic glycerophosphates and analogs thereof |
-
1999
- 1999-03-25 IL IL12917899A patent/IL129178A0/xx unknown
-
2000
- 2000-03-24 KR KR1020017012158A patent/KR20010112364A/ko not_active Withdrawn
- 2000-03-24 WO PCT/IL2000/000185 patent/WO2000057865A2/en not_active Ceased
- 2000-03-24 AT AT00912877T patent/ATE290385T1/de not_active IP Right Cessation
- 2000-03-24 NZ NZ514525A patent/NZ514525A/en unknown
- 2000-03-24 JP JP2000607616A patent/JP2002540146A/ja active Pending
- 2000-03-24 EP EP00912877A patent/EP1162959B1/en not_active Expired - Lifetime
- 2000-03-24 DE DE60018554T patent/DE60018554T2/de not_active Expired - Fee Related
- 2000-03-24 CA CA002368597A patent/CA2368597A1/en not_active Abandoned
- 2000-03-24 MX MXPA01009650A patent/MXPA01009650A/es not_active Application Discontinuation
- 2000-03-24 CN CN00806738A patent/CN1348375A/zh active Pending
- 2000-03-24 HK HK02101620.4A patent/HK1042038A1/zh unknown
- 2000-03-24 BR BR0009296-7A patent/BR0009296A/pt not_active IP Right Cessation
- 2000-03-24 US US09/936,922 patent/US6914056B1/en not_active Expired - Fee Related
- 2000-03-24 RU RU2001128743/15A patent/RU2247557C2/ru not_active IP Right Cessation
- 2000-03-24 AU AU34517/00A patent/AU768911B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2247557C2 (ru) | 2005-03-10 |
| AU3451700A (en) | 2000-10-16 |
| WO2000057865A9 (en) | 2001-11-15 |
| CN1348375A (zh) | 2002-05-08 |
| EP1162959B1 (en) | 2005-03-09 |
| NZ514525A (en) | 2003-10-31 |
| MXPA01009650A (es) | 2002-07-02 |
| AU768911B2 (en) | 2004-01-08 |
| WO2000057865A3 (en) | 2001-06-28 |
| JP2002540146A (ja) | 2002-11-26 |
| HK1042038A1 (zh) | 2002-08-02 |
| DE60018554D1 (de) | 2005-04-14 |
| US6914056B1 (en) | 2005-07-05 |
| WO2000057865A2 (en) | 2000-10-05 |
| CA2368597A1 (en) | 2000-10-05 |
| EP1162959A2 (en) | 2001-12-19 |
| KR20010112364A (ko) | 2001-12-20 |
| ATE290385T1 (de) | 2005-03-15 |
| IL129178A0 (en) | 2000-02-17 |
| DE60018554T2 (de) | 2006-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60018554D1 (de) | Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten | |
| Karczmar | Acute and long lasting central actions of organophosphorus agents | |
| Ichihara et al. | Neurological disorders in three workers exposed to 1-bromopropane | |
| EP0348353A3 (en) | The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases | |
| DE69004837D1 (de) | Verwendung von 5-Methyltetrahydrofolsäure, 5-Formyltetrahydrofolsäure sowie deren pharmazeutisch geeigneten Salzen zur Herstellung von Arzneimitteln mit gesteuerter Freigabe und wirksam in der Therapie organisch mentaler Störungen sowie die entsprechenden Arzneimittel. | |
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| ATE444077T1 (de) | Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen | |
| EP0616032A3 (en) | Preventive or therapeutic agents against Alzheimer's disease, a screening method and the human tau kinase protein. | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| ES2169127T3 (es) | Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco. | |
| BR9714677A (pt) | "enantiÈmeros 3-piridila e seu uso como analgésicos" | |
| ATE230989T1 (de) | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems | |
| DE3779149D1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| PL342078A1 (en) | Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas | |
| NZ335726A (en) | Use of nimesulide for treating neurodegenerative conditions; and pharmaceuticals comprising them | |
| Nybäck et al. | Effects of piracetam on brain monoamine metabolism and serum prolactin levels in the rat | |
| Kerwin | From pharmacological profiles to clinical outcomes | |
| DE69636934D1 (de) | Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen | |
| NO991292L (no) | Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser | |
| BR9406034A (pt) | Derivados de imidazoloquinoxalinonas como antagonistas de eaa. | |
| DE60039579D1 (de) | Humane adulte astrozyten, sowie deren herstellung und verwendung | |
| WO2002030411A8 (en) | Treatment of apoptotic cell death | |
| OHNISHI et al. | Polyneuropathy due to ethylene oxide, propylene oxide, and butylene oxide | |
| Licht et al. | The effect of chronic lithium treatment on the calibre of axons and nerve fibres in the rat sural nerve | |
| Ovtscharoff | Cytochemical Localization of Choline Acetyltransferase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ,8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009. |